Hypoadiponectinemia in patients with paroxysmal atrial fibrillation

Korean Circulation Journal

Volumn 42, Issue 10, 2012, Pages 668-673

  Choi, Byung Joo ^a   Heo, Jung Ho ^a   Choi, In Soo ^a   Lee, Si Won ^a   Kim, Hyun Soo ^a   Lee, Jae Woo ^a   Cha, Tae Joon ^a  

^a Kosin University   (South Korea)

Author keywords

Adiponectin; Atrial fibrillation

Indexed keywords

ADIPONECTIN; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; HYPOADIPONECTINEMIA; LABORATORY TEST; MALE; METABOLIC PARAMETERS; PROTEIN BLOOD LEVEL;

EID: 84869834670     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2012.42.10.668     Document Type: Article

References (30)

1. Goette A, Arndt M, Röcken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101:2678-81.
2. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91.
3. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92.
4. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 2009;11:1032-6.
5. Nicolaou VN, Papadakis JE, Karatzis EN, Dermitzaki SI, Tsakiris AK, Skoufas PD. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology 2007;58:21-5.
6. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007;116(11 Suppl):I213-9.
7. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49:531-8.
8. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Aatrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50.
9. McNamara RL, Brass LM, Drozda JP Jr, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol 2004;44:475-95.
10. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/ SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance: endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Soc Echocardiogr 2007;20:787-805.
11. Celik T, Iyisoy A. A new villain of the village: hypoadiponectinemia. Int J Cardiol 2009;137:54-5.
12. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
13. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420-4.
14. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829-35.
15. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723-30.
16. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-41.
17. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129-34.
18. Shimano M, Shibata R, Tsuji Y, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008;72:1120-4.
19. Rienstra M, Sun JX, Lubitz SA, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012;163:119-24.
20. Kumagai K. Upstream approach for atrial fibrillation. Nihon Yakurigaku Zasshi 2010;135:59-61.
21. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
22. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-7.
23. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009;24:1876-83.
24. Yenicesu M, Yilmaz MI, Caglar K, et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005;99:c115-21.
25. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-7.
26. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
27. Della Mea P, Lupia M, Bandolin V, et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005;18:30-5.
28. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
29. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
30. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-62.